Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
In a randomized study of second-line therapy, treatment with nivolumab, an anti–PD-1 antibody, resulted in responses in more people and in better overall survival than did docetaxel. Squamous-cell carcinoma represents approximately 30% of all cases of non–small-cell lung cancer (NSCLC). 1 Treatment...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2015-07, Vol.373 (2), p.123-135 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 135 |
|---|---|
| container_issue | 2 |
| container_start_page | 123 |
| container_title | The New England journal of medicine |
| container_volume | 373 |
| creator | Brahmer, Julie Reckamp, Karen L Baas, Paul Crinò, Lucio Eberhardt, Wilfried E.E Poddubskaya, Elena Antonia, Scott Pluzanski, Adam Vokes, Everett E Holgado, Esther Waterhouse, David Ready, Neal Gainor, Justin Arén Frontera, Osvaldo Havel, Libor Steins, Martin Garassino, Marina C Aerts, Joachim G Domine, Manuel Paz-Ares, Luis Reck, Martin Baudelet, Christine Harbison, Christopher T Lestini, Brian Spigel, David R |
| description | In a randomized study of second-line therapy, treatment with nivolumab, an anti–PD-1 antibody, resulted in responses in more people and in better overall survival than did docetaxel.
Squamous-cell carcinoma represents approximately 30% of all cases of non–small-cell lung cancer (NSCLC).
1
Treatment for advanced squamous-cell NSCLC remains an unmet need; little therapeutic progress has been made since the approval of docetaxel for second-line treatment in 1999.
2
–
4
Most new agents for the treatment of NSCLC are not indicated for this subtype because of their toxicity or lack of efficacy or because their activity is limited to tumors with specific genetic alterations that are rarely found in squamous-cell NSCLC.
5
–
7
Furthermore, no single-agent therapy has resulted in better survival than that seen with docetaxel.
The programmed death 1 (PD-1) . . . |
| doi_str_mv | 10.1056/NEJMoa1504627 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4681400</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1695760677</sourcerecordid><originalsourceid>FETCH-LOGICAL-c577t-ad0a03067298fd092dd7eb20116c25f7213ae2739c681832211ba0c550548a4d3</originalsourceid><addsrcrecordid>eNp1kV1LHDEUhoNYdF176a0MSMGbqSffMzcF2Wo_2K6I9TpkM1k7yyTRZGfRO_-D_9Bf0thdRQvm5kDOw8N5eRHaw_AZAxdHk5Ofv4LGHJggcgMNMKe0ZAzEJhoAkKpksqbbaCelOeSHWb2FtonIGwZygM4n7TJ0vdPTYmlj6lPxNRi70Le2K1pfHDdL7Y1tioubXrvQp3Jku66YBP94_3DhdNetPsa9vypGT2jcRR9mukv243oO0eXpye_R93J89u3H6HhcGi7lotQNaKAgJKmrWQM1aRpppwQwFobwmSSYakskrY2ocEUJwXiqwXAOnFWaNXSIvqy81_3U2cZYv4i6U9exdTreqaBb9Xbj2z_qKiwVy0IGkAWHa0EMN71NC-XaZHIa7W1OqrCouRT5QpnRg__Qeeijz_H-UYQKIUimyhVlYkgp2tnLMRjUU1nqTVmZ33-d4IV-bicDn1aAc0l5O3fviP4Cdleasw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1695236662</pqid></control><display><type>article</type><title>Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>New England Journal of Medicine</source><creator>Brahmer, Julie ; Reckamp, Karen L ; Baas, Paul ; Crinò, Lucio ; Eberhardt, Wilfried E.E ; Poddubskaya, Elena ; Antonia, Scott ; Pluzanski, Adam ; Vokes, Everett E ; Holgado, Esther ; Waterhouse, David ; Ready, Neal ; Gainor, Justin ; Arén Frontera, Osvaldo ; Havel, Libor ; Steins, Martin ; Garassino, Marina C ; Aerts, Joachim G ; Domine, Manuel ; Paz-Ares, Luis ; Reck, Martin ; Baudelet, Christine ; Harbison, Christopher T ; Lestini, Brian ; Spigel, David R</creator><creatorcontrib>Brahmer, Julie ; Reckamp, Karen L ; Baas, Paul ; Crinò, Lucio ; Eberhardt, Wilfried E.E ; Poddubskaya, Elena ; Antonia, Scott ; Pluzanski, Adam ; Vokes, Everett E ; Holgado, Esther ; Waterhouse, David ; Ready, Neal ; Gainor, Justin ; Arén Frontera, Osvaldo ; Havel, Libor ; Steins, Martin ; Garassino, Marina C ; Aerts, Joachim G ; Domine, Manuel ; Paz-Ares, Luis ; Reck, Martin ; Baudelet, Christine ; Harbison, Christopher T ; Lestini, Brian ; Spigel, David R</creatorcontrib><description>In a randomized study of second-line therapy, treatment with nivolumab, an anti–PD-1 antibody, resulted in responses in more people and in better overall survival than did docetaxel.
Squamous-cell carcinoma represents approximately 30% of all cases of non–small-cell lung cancer (NSCLC).
1
Treatment for advanced squamous-cell NSCLC remains an unmet need; little therapeutic progress has been made since the approval of docetaxel for second-line treatment in 1999.
2
–
4
Most new agents for the treatment of NSCLC are not indicated for this subtype because of their toxicity or lack of efficacy or because their activity is limited to tumors with specific genetic alterations that are rarely found in squamous-cell NSCLC.
5
–
7
Furthermore, no single-agent therapy has resulted in better survival than that seen with docetaxel.
The programmed death 1 (PD-1) . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1504627</identifier><identifier>PMID: 26028407</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adult ; Aged ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Apoptosis ; B7-H1 Antigen - metabolism ; Body weight ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - mortality ; Cell survival ; Chemotherapy ; Death ; Drug dosages ; Female ; Humans ; Immune checkpoint inhibitors ; Immunoglobulin G ; Immunotherapy ; Ligands ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Male ; Middle Aged ; Monoclonal antibodies ; Non-small cell lung carcinoma ; Patients ; PD-1 protein ; PD-L1 protein ; Programmed Cell Death 1 Receptor - immunology ; Squamous cell carcinoma ; Survival Analysis ; Targeted cancer therapy ; Taxoids - adverse effects ; Taxoids - therapeutic use</subject><ispartof>The New England journal of medicine, 2015-07, Vol.373 (2), p.123-135</ispartof><rights>Copyright © 2015 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c577t-ad0a03067298fd092dd7eb20116c25f7213ae2739c681832211ba0c550548a4d3</citedby><cites>FETCH-LOGICAL-c577t-ad0a03067298fd092dd7eb20116c25f7213ae2739c681832211ba0c550548a4d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1504627$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1504627$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,776,780,881,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26028407$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brahmer, Julie</creatorcontrib><creatorcontrib>Reckamp, Karen L</creatorcontrib><creatorcontrib>Baas, Paul</creatorcontrib><creatorcontrib>Crinò, Lucio</creatorcontrib><creatorcontrib>Eberhardt, Wilfried E.E</creatorcontrib><creatorcontrib>Poddubskaya, Elena</creatorcontrib><creatorcontrib>Antonia, Scott</creatorcontrib><creatorcontrib>Pluzanski, Adam</creatorcontrib><creatorcontrib>Vokes, Everett E</creatorcontrib><creatorcontrib>Holgado, Esther</creatorcontrib><creatorcontrib>Waterhouse, David</creatorcontrib><creatorcontrib>Ready, Neal</creatorcontrib><creatorcontrib>Gainor, Justin</creatorcontrib><creatorcontrib>Arén Frontera, Osvaldo</creatorcontrib><creatorcontrib>Havel, Libor</creatorcontrib><creatorcontrib>Steins, Martin</creatorcontrib><creatorcontrib>Garassino, Marina C</creatorcontrib><creatorcontrib>Aerts, Joachim G</creatorcontrib><creatorcontrib>Domine, Manuel</creatorcontrib><creatorcontrib>Paz-Ares, Luis</creatorcontrib><creatorcontrib>Reck, Martin</creatorcontrib><creatorcontrib>Baudelet, Christine</creatorcontrib><creatorcontrib>Harbison, Christopher T</creatorcontrib><creatorcontrib>Lestini, Brian</creatorcontrib><creatorcontrib>Spigel, David R</creatorcontrib><title>Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In a randomized study of second-line therapy, treatment with nivolumab, an anti–PD-1 antibody, resulted in responses in more people and in better overall survival than did docetaxel.
Squamous-cell carcinoma represents approximately 30% of all cases of non–small-cell lung cancer (NSCLC).
1
Treatment for advanced squamous-cell NSCLC remains an unmet need; little therapeutic progress has been made since the approval of docetaxel for second-line treatment in 1999.
2
–
4
Most new agents for the treatment of NSCLC are not indicated for this subtype because of their toxicity or lack of efficacy or because their activity is limited to tumors with specific genetic alterations that are rarely found in squamous-cell NSCLC.
5
–
7
Furthermore, no single-agent therapy has resulted in better survival than that seen with docetaxel.
The programmed death 1 (PD-1) . . .</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis</subject><subject>B7-H1 Antigen - metabolism</subject><subject>Body weight</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Cell survival</subject><subject>Chemotherapy</subject><subject>Death</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Humans</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunoglobulin G</subject><subject>Immunotherapy</subject><subject>Ligands</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>PD-L1 protein</subject><subject>Programmed Cell Death 1 Receptor - immunology</subject><subject>Squamous cell carcinoma</subject><subject>Survival Analysis</subject><subject>Targeted cancer therapy</subject><subject>Taxoids - adverse effects</subject><subject>Taxoids - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kV1LHDEUhoNYdF176a0MSMGbqSffMzcF2Wo_2K6I9TpkM1k7yyTRZGfRO_-D_9Bf0thdRQvm5kDOw8N5eRHaw_AZAxdHk5Ofv4LGHJggcgMNMKe0ZAzEJhoAkKpksqbbaCelOeSHWb2FtonIGwZygM4n7TJ0vdPTYmlj6lPxNRi70Le2K1pfHDdL7Y1tioubXrvQp3Jku66YBP94_3DhdNetPsa9vypGT2jcRR9mukv243oO0eXpye_R93J89u3H6HhcGi7lotQNaKAgJKmrWQM1aRpppwQwFobwmSSYakskrY2ocEUJwXiqwXAOnFWaNXSIvqy81_3U2cZYv4i6U9exdTreqaBb9Xbj2z_qKiwVy0IGkAWHa0EMN71NC-XaZHIa7W1OqrCouRT5QpnRg__Qeeijz_H-UYQKIUimyhVlYkgp2tnLMRjUU1nqTVmZ33-d4IV-bicDn1aAc0l5O3fviP4Cdleasw</recordid><startdate>20150709</startdate><enddate>20150709</enddate><creator>Brahmer, Julie</creator><creator>Reckamp, Karen L</creator><creator>Baas, Paul</creator><creator>Crinò, Lucio</creator><creator>Eberhardt, Wilfried E.E</creator><creator>Poddubskaya, Elena</creator><creator>Antonia, Scott</creator><creator>Pluzanski, Adam</creator><creator>Vokes, Everett E</creator><creator>Holgado, Esther</creator><creator>Waterhouse, David</creator><creator>Ready, Neal</creator><creator>Gainor, Justin</creator><creator>Arén Frontera, Osvaldo</creator><creator>Havel, Libor</creator><creator>Steins, Martin</creator><creator>Garassino, Marina C</creator><creator>Aerts, Joachim G</creator><creator>Domine, Manuel</creator><creator>Paz-Ares, Luis</creator><creator>Reck, Martin</creator><creator>Baudelet, Christine</creator><creator>Harbison, Christopher T</creator><creator>Lestini, Brian</creator><creator>Spigel, David R</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150709</creationdate><title>Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer</title><author>Brahmer, Julie ; Reckamp, Karen L ; Baas, Paul ; Crinò, Lucio ; Eberhardt, Wilfried E.E ; Poddubskaya, Elena ; Antonia, Scott ; Pluzanski, Adam ; Vokes, Everett E ; Holgado, Esther ; Waterhouse, David ; Ready, Neal ; Gainor, Justin ; Arén Frontera, Osvaldo ; Havel, Libor ; Steins, Martin ; Garassino, Marina C ; Aerts, Joachim G ; Domine, Manuel ; Paz-Ares, Luis ; Reck, Martin ; Baudelet, Christine ; Harbison, Christopher T ; Lestini, Brian ; Spigel, David R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c577t-ad0a03067298fd092dd7eb20116c25f7213ae2739c681832211ba0c550548a4d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis</topic><topic>B7-H1 Antigen - metabolism</topic><topic>Body weight</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Cell survival</topic><topic>Chemotherapy</topic><topic>Death</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Humans</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunoglobulin G</topic><topic>Immunotherapy</topic><topic>Ligands</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>PD-L1 protein</topic><topic>Programmed Cell Death 1 Receptor - immunology</topic><topic>Squamous cell carcinoma</topic><topic>Survival Analysis</topic><topic>Targeted cancer therapy</topic><topic>Taxoids - adverse effects</topic><topic>Taxoids - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brahmer, Julie</creatorcontrib><creatorcontrib>Reckamp, Karen L</creatorcontrib><creatorcontrib>Baas, Paul</creatorcontrib><creatorcontrib>Crinò, Lucio</creatorcontrib><creatorcontrib>Eberhardt, Wilfried E.E</creatorcontrib><creatorcontrib>Poddubskaya, Elena</creatorcontrib><creatorcontrib>Antonia, Scott</creatorcontrib><creatorcontrib>Pluzanski, Adam</creatorcontrib><creatorcontrib>Vokes, Everett E</creatorcontrib><creatorcontrib>Holgado, Esther</creatorcontrib><creatorcontrib>Waterhouse, David</creatorcontrib><creatorcontrib>Ready, Neal</creatorcontrib><creatorcontrib>Gainor, Justin</creatorcontrib><creatorcontrib>Arén Frontera, Osvaldo</creatorcontrib><creatorcontrib>Havel, Libor</creatorcontrib><creatorcontrib>Steins, Martin</creatorcontrib><creatorcontrib>Garassino, Marina C</creatorcontrib><creatorcontrib>Aerts, Joachim G</creatorcontrib><creatorcontrib>Domine, Manuel</creatorcontrib><creatorcontrib>Paz-Ares, Luis</creatorcontrib><creatorcontrib>Reck, Martin</creatorcontrib><creatorcontrib>Baudelet, Christine</creatorcontrib><creatorcontrib>Harbison, Christopher T</creatorcontrib><creatorcontrib>Lestini, Brian</creatorcontrib><creatorcontrib>Spigel, David R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brahmer, Julie</au><au>Reckamp, Karen L</au><au>Baas, Paul</au><au>Crinò, Lucio</au><au>Eberhardt, Wilfried E.E</au><au>Poddubskaya, Elena</au><au>Antonia, Scott</au><au>Pluzanski, Adam</au><au>Vokes, Everett E</au><au>Holgado, Esther</au><au>Waterhouse, David</au><au>Ready, Neal</au><au>Gainor, Justin</au><au>Arén Frontera, Osvaldo</au><au>Havel, Libor</au><au>Steins, Martin</au><au>Garassino, Marina C</au><au>Aerts, Joachim G</au><au>Domine, Manuel</au><au>Paz-Ares, Luis</au><au>Reck, Martin</au><au>Baudelet, Christine</au><au>Harbison, Christopher T</au><au>Lestini, Brian</au><au>Spigel, David R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2015-07-09</date><risdate>2015</risdate><volume>373</volume><issue>2</issue><spage>123</spage><epage>135</epage><pages>123-135</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>In a randomized study of second-line therapy, treatment with nivolumab, an anti–PD-1 antibody, resulted in responses in more people and in better overall survival than did docetaxel.
Squamous-cell carcinoma represents approximately 30% of all cases of non–small-cell lung cancer (NSCLC).
1
Treatment for advanced squamous-cell NSCLC remains an unmet need; little therapeutic progress has been made since the approval of docetaxel for second-line treatment in 1999.
2
–
4
Most new agents for the treatment of NSCLC are not indicated for this subtype because of their toxicity or lack of efficacy or because their activity is limited to tumors with specific genetic alterations that are rarely found in squamous-cell NSCLC.
5
–
7
Furthermore, no single-agent therapy has resulted in better survival than that seen with docetaxel.
The programmed death 1 (PD-1) . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>26028407</pmid><doi>10.1056/NEJMoa1504627</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2015-07, Vol.373 (2), p.123-135 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4681400 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; New England Journal of Medicine |
| subjects | Adult Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Apoptosis B7-H1 Antigen - metabolism Body weight Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - mortality Cell survival Chemotherapy Death Drug dosages Female Humans Immune checkpoint inhibitors Immunoglobulin G Immunotherapy Ligands Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Middle Aged Monoclonal antibodies Non-small cell lung carcinoma Patients PD-1 protein PD-L1 protein Programmed Cell Death 1 Receptor - immunology Squamous cell carcinoma Survival Analysis Targeted cancer therapy Taxoids - adverse effects Taxoids - therapeutic use |
| title | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A28%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nivolumab%20versus%20Docetaxel%20in%20Advanced%20Squamous-Cell%20Non%E2%80%93Small-Cell%20Lung%20Cancer&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Brahmer,%20Julie&rft.date=2015-07-09&rft.volume=373&rft.issue=2&rft.spage=123&rft.epage=135&rft.pages=123-135&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa1504627&rft_dat=%3Cproquest_pubme%3E1695760677%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1695236662&rft_id=info:pmid/26028407&rfr_iscdi=true |